BCRX - BioCryst Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
270,827
270,827
157,170
17,812
48,835
Cost of revenue
6,594
6,594
7,264
1,676
4,101
Gross profit
264,233
264,233
149,906
16,136
44,734
Operating expenses
Research development
253,297
253,297
208,808
122,964
107,068
Selling general and administrative
159,371
159,371
118,818
67,929
37,121
Total operating expenses
412,668
412,668
327,626
190,893
144,189
Operating income or loss
-148,435
-148,435
-177,720
-174,757
-99,455
Interest expense
99,092
99,092
59,294
14,501
11,892
Total other income/expenses net
-1,984
-1,984
55,143
-2,976
517
Income before tax
-244,384
-244,384
-181,809
-182,814
-108,897
Income tax expense
2,733
2,733
2,253
-
-
Income from continuing operations
-247,117
-247,117
-184,062
-182,814
-108,897
Net income
-247,117
-247,117
-184,062
-182,814
-108,897
Net income available to common shareholders
-247,117
-247,117
-184,062
-182,814
-108,897
Basic EPS
-
-
-1.03
-1.09
-0.94
Diluted EPS
-
-
-1.03
-1.09
-0.94
Basic average shares
-
-
179,117
167,267
115,600
Diluted average shares
-
-
179,117
167,267
115,600
EBITDA
-
-145,292
-122,515
-168,313
-97,005